ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Tsumura & Co.

Business Summary

Tsumura & Co. engages in the manufacture and sale of pharmaceutical products. It manufactures and sells Kampo medicine, a traditional form of medicine in Japan. The company is also involved in the procurement, sorting, production, processing, and storage of botanical raw materials; production and sale of Kampo extract intermediates; and provision of logistics, storage, distribution, and materials handling services. Its products include Chujoto, L'amour, Tsumura-Kampo Kakkonto, Tsumura-Kampo Otsujito, and Tsumura-Kampo Orengedokuto. The company was founded by Jusha Tsumura on April 10, 1893 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue123,248M1,133.56M
Gross Profit72,500M666.81M
Operating income18,877M173.62M
Income before tax19,223M176.80M
Net income13,765M126.60M
EBITDA25,283M232.53M
Diluted EPS179.961.65
Dividends Per Share640.58
Total Assets312,589M2,895.54M
Total liabilities99,537M922.02M
Total equity205,377M1,902.43M
Operating cash flow18,191M167.31M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 112,618M 114,957M 117,882M 120,906M 123,248M
Gross Profit 67,570M 65,500M 68,275M 71,456M 72,500M
Operating income 19,826M 15,984M 17,051M 18,521M 18,877M
Income before tax 18,898M 17,184M 20,284M 19,897M 19,223M
Net income 12,557M 12,489M 14,505M 14,594M 13,765M
EBITDA 24,886M 21,613M 23,208M 24,883M 25,283M
Diluted EPS 178.05 179.44 200.54 190.86 179.96
Dividends Per Share 64 64 64 64 64
Total Assets 222,468M 222,008M 292,379M 287,322M 312,589M
Total liabilities 66,766M 64,608M 95,845M 81,178M 99,537M
Total equity 152,976M 154,784M 193,600M 201,817M 205,377M
Operating cash flow 17,570M 21,065M 21,066M 5,450M 18,191M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 937.82M 1,061.59M 1,063.60M 1,090.27M 1,133.56M
Gross Profit 562.68M 604.87M 616.02M 644.35M 666.81M
Operating income 165.10M 147.60M 153.84M 167.01M 173.62M
Income before tax 157.37M 158.68M 183.01M 179.42M 176.80M
Net income 104.56M 115.33M 130.87M 131.60M 126.60M
EBITDA 207.23M 199.58M 209.39M 224.38M 232.53M
Diluted EPS 1.48 1.65 1.80 1.72 1.65
Dividends Per Share 0.53 0.59 0.57 0.57 0.58
Total Assets 1,979.34M 1,992.35M 2,749.21M 2,595.85M 2,895.54M
Total liabilities 594.02M 579.80M 901.22M 733.41M 922.02M
Total equity 1,361.05M 1,389.06M 1,820.40M 1,823.34M 1,902.43M
Operating cash flow 146.31M 194.52M 190.07M 49.14M 167.31M

Valuation Measures

Mar 2020
PER15.29
ROA4.58%
ROE6.76%
Operating margin15.31%
Profit margin11.16%

Key executives

  • Executive President & Representative Director: Terukazu Kato
  • Director & Senior Manager-Compliance: Yasunori Fuji
  • Executive Officer & Manager-Personnel: Shuji Sugawara
  • Secretary, Executive Officer & Head-Health Care: Ryouichi Murata
  • Managing Executive Officer: Ryuji Takasaki

Shareholders

  • Invesco Asset Management (Japan) Ltd. (11.9%)
  • Ping An Insurance (Group) Co. of China Ltd. (9.9%)
  • Marathon Asset Management LLP (5.1%)
  • Sompo Asset Management Co., Ltd. (4.0%)
  • JPMorgan Asset Management (Japan) Ltd. (3.8%)
  • Mitsubishi UFJ Financial Group, Inc. (3.5%)
  • Baillie Gifford & Co. (2.8%)
  • The Vanguard Group, Inc. (2.4%)
  • Tsumura & Co. Employee Stock Ownership Plan (2.3%)
  • Bright Ride Ltd. (2.2%)

Contact Details

Related Companies

  • Ping An Tsumura Co., Ltd.
  • Tsumura Board Incentive Plan
  • Shenzhen Tsumura Medicine Co. Ltd.
  • Shanghai Tsumura Pharmaceuticals Co. Ltd.
  • Logitem Tsumura KK
  • Tsumura USA, Inc.
  • Tsumura & Co. Employee Stock Ownership Plan

Competitors

    Last Updated on 11 Aug, 2020

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Try 1 month for $0.99

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends July 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media